1
|
Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: what do we know in 2019? CLINICAL MEDICINE INSIGHTS. REPRODUCTIVE HEALTH 2019; 13:1179558119871921. [PMID: 31523136 PMCID: PMC6734626 DOI: 10.1177/1179558119871921] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Accepted: 07/31/2019] [Indexed: 12/16/2022]
Abstract
Polycystic ovary syndrome (PCOS) and hyperprolactinemia (HPRL) are the two most common etiologies of anovulation in women. Since the 1950s, some authors think that there is a pathophysiological link between PCOS and HPRL. Since then, many authors have speculated about the link between these two endocrine entities, but no hypothesis proposed so far could ever be confirmed. Furthermore, PCOS and HPRL are frequent endocrine diseases and a fortuitous association cannot be excluded. The evolution of knowledge about PCOS and HPRL shows that studies conducted before the 2000s are obsolete given current knowledge. Indeed, most of the studies were conducted before consensual diagnosis criteria of PCOS and included small numbers of patients. In addition, the investigation of HPRL in these studies relied on obsolete methods and did not look for the presence of macroprolactinemia. It is therefore possible that HPRL that has been attributed to PCOS corresponded in fact to macroprolactinemia or to pituitary microadenomas of small sizes that could not be detected with the imaging methods of the time. Recent studies that have conducted a rigorous etiological investigation show that HPRL found in PCOS correspond either to non-permanent increase of prolactin levels, to macroprolactinemia or to other etiologies. None of this recent study found HPRL related to PCOS in these patients. Thus, the link between PCOS and HPRL seems to be more of a myth than a well-established medical reality and we believe that the discovery of an HPRL in a PCOS patient needs a standard etiological investigation of HPRL.
Collapse
Affiliation(s)
- Clémence Delcour
- Department of Obstetrics and Gynecology, Robert-Debré hospital, AP-HP, Paris, France
- INSERM, U1141, Paris Diderot university, Sorbonne Paris Cité, Paris, France
| | - Geoffroy Robin
- CHU Lille, Department of Reproductive Medicine & Lille University, Lille, France
- EA 4308, Lille University, Lille, France
| | - Jacques Young
- Department of Endocrinology and Reproductive Medicine, CHU Kremlin Bicetre, Paris, France
| | - Didier Dewailly
- INSERM U1172 Team 2, JPARC, Université de Lille, 59000 Lille, France
- Didier Dewailly, INSERM U1172 Team 2, JPARC, Université de LilleI, 52 rue Paul Duez, Lille, 59000, France.
| |
Collapse
|
2
|
Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007; 23:267-72. [PMID: 17558684 DOI: 10.1080/09513590701297708] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
The aims of the present study were to identify the cause of hyperprolactinemia in polycystic ovary syndrome (PCOS) and to compare prolactin (PRL) levels between PCOS women without hyperprolactinemia and women with insulin resistance and without PCOS. A group of 82 women (age: 27.1 +/- 7.6 years) with PCOS was included in the study. Their PRL levels were measured and compared with those of women with insulin resistance without PCOS (controls; n = 42; age: 29.2 +/- 8.2 years). Among the 82 PCOS women, 13 (16%) presented high PRL levels (103.9 +/- 136.0 microg/l). The causes of hyperprolactinemia were: pituitary tumor (responding to cabergoline) in nine cases (69%; PRL range: 28.6 - 538 microg/l); oral hormonal contraceptive treatment in two cases (15%; PRL: 46 and 55 microg/l, respectively); and use of buspirone and tianeptine in one case (8%; PRL: 37.1 microg/l); one case (8%; PRL: 34.4 microg/l) had macroprolactinemia. In drug-induced hyperprolactinemic patients PRL levels normalized after treatment interruption. The average PRL level in the 69 remaining patients was 12.1 +/- 5.5 microg/l, a value not statistically different from that of the control group (11.8 +/- 4.9 microg/l). This result leads us to conclude that PCOS patients with increased PRL levels must be investigated for other causes of hyperprolactinemia, because hyperprolactinemia is not a clinical manifestation of PCOS.
Collapse
|
3
|
Fox R. Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. Aust N Z J Obstet Gynaecol 1999; 39:63-8. [PMID: 10099753 DOI: 10.1111/j.1479-828x.1999.tb03447.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The transvaginal ultrasound appearances of the ovary were determined in women with clinical and endocrine features of polycystic ovarian disease (PCOD) and apparently normal women. At scan the number of small follicles were counted and ovarian volume was calculated. The maximum width of the ovarian cortex was also measured. Blood was sent for measurement of LH, FSH and testosterone. The women with oligomenorrhoea were scanned at random and the normal women were seen within the first 5 days of the start of menstruation. There were significant differences between median values for the 2 groups in terms of number of small follicles, ovarian volume and stromal width; the ovaries of the hirsute women had more follicles, were of larger volume, and had greater stromal width. The 2 ranges for number of follicles did overlap, however. Four hirsute oligomenorrhoeic women had a normal number of follicles; all 4 had the several clinical and endocrine features indicative of PCOD. These data suggest that the classical ultrasound features of PCOD are not consistently present and that the absence of increased follicularity at scan should not necessarily deter clinicians from making the functional diagnosis of PCOD.
Collapse
Affiliation(s)
- R Fox
- University of Bristol, Department of Obstetrics and Gynaecology, St. Michael's Hospital, United Kingdom
| |
Collapse
|
4
|
Hudson RW, Lochnan HA, Danby FW, Margesson LJ, Strang BK, Kimmett SM. 11β-hydroxyandrostenedione: a marker of adrenal function in hirsutism**Supported by the Physicians of Ontario through a grant from the Physicians’ Services Incorporated Foundation, Toronto, Ontario, Canada.††Presented in part at the 35th Annual Meeting of the Canadian Fertility and Andrology Society, Vancouver, British Columbia, Canada, November 9 to 11, 1989. Fertil Steril 1990. [DOI: 10.1016/s0015-0282(16)54006-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Affiliation(s)
- S Franks
- Department of Obstetrics and Gynaecology, St Mary's Hospital Medical School, London, UK
| |
Collapse
|
6
|
Ferrari E, Bossolo PA, Foppa S, Dalzano M, Comis S, Morelli MP, Peveri V, Mengozzi A. Prolactin secretion in polycystic ovary syndrome: circadian rhythmicity and dynamic aspects. Gynecol Endocrinol 1988; 2:101-11. [PMID: 3188970 DOI: 10.3109/09513598809023618] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The circadian rhythms of plasma prolactin (PRL) and cortisol and of oral temperature were simultaneously studied in 24 women with polycystic ovary syndrome (PCOS). The PRL response to thyrotropin-releasing hormone (TRH) and domperidone was also evaluated in some of these patients. The physiological circadian chrono-organization of prolactin and cortisol secretion and of oral temperature was maintained in PCOS. The PRL responsiveness to the specific stimulations fell within normal limits. These results do not support the hypothesis of an impaired central dopaminergic regulation of prolactin secretion in PCOS.
Collapse
Affiliation(s)
- E Ferrari
- Department of Internal Medicine and Medical Therapy, University of Pavia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Venturoli S, Porcu E, Fabbri R, Magrini O, Gammi L, Paradisi R, Forcacci M, Bolzani R, Flamigni C. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1988; 28:93-107. [PMID: 3139335 DOI: 10.1111/j.1365-2265.1988.tb01208.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Pulsatile secretion of LH, FSH, PRL, oestradiol and oestrone was studied in a group of 16 patients with micropolycystic ovary syndrome (PCOS) and compared with that of normal ovulatory women in the fifth to sixth day of the cycle. Hormone concentrations were measured at 10 min intervals for 8 h starting at 0930 h. In seven subjects, the study was prolonged for 24 h, with 20 min interval samples, in an attempt to evaluate the circadian rhythm of LH by cosinor analysis. Significant fluctuations occurred in the concentration of each hormone. Values shown are mean +/- SD. PCOS subjects had high LH mean values (27.9 +/- 5.9 IU/l) (P less than 0.005). LH pulse amplitude was higher than controls (11.6 +/- 3.7 IU/l versus 5.2 +/- 1.8 IU/l; P less than 0.005) while no consistent changes in frequency or interpulse interval (62.0 +/- 10.7 min versus 65.8 +/- 19.2 min; P = NS) were found. A mean of 4.8 +/- 1.2 pulses of FSH occurred in 8 h and the mean pulse amplitude was 2.68 +/- 1.11 with no differences from controls. All patients were normoprolactinaemic. A mean of 5.5 +/- 1.9 pulses occurred in 8 h, the interpulse interval was 76.1 +/- 14.4 min and the amplitude was 2.87 +/- 0.76 ng/ml and there were no significant differences from controls; 75% of PRL pulses showed a temporal relationship with LH pulses. Oestrone mean basal values were higher in PCOS (47.2 +/- 12.5 pg/ml) than controls (32.0 +/- 9.9 pg/ml; P less than 0.02), while no differences were observed as regards oestradiol. Oestradiol pulse amplitude was nearly the same as oestrone (43.6 +/- 18.8 pg/ml and 37.7 +/- 16.1 pg/ml, respectively); 6.0 +/- 2.2 pulses and 6.0 +/- 1.6 pulses occurred in 8 h with an interpulse interval of 81.1 +/- 27.1 min and 71.8 +/- 11.1 min, respectively. Sixty-five per cent of LH pulses were followed by an oestradiol and oestrone peak. The mean time of the appearance was 17 +/- 15 min and 25 +/- 23 min, respectively. In the PCOS group a consistent 24 h rhythm in mean plasma LH levels was found with the highest hormone values at 1720 h (P less than 0.05) unrelated to apparent sleep and different from that of adult women. Pulse frequency showed a significant slowing during the night with the longest interpulse interval at 0327 h (P less than 0.03) while no significant periodicity was observed in LH pulse amplitude.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- S Venturoli
- Institute of Reproductive Physiology and Pathology, University of Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Prelević GM, Würzburger MI, Perić LA. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. J Endocrinol Invest 1987; 10:389-95. [PMID: 3119696 DOI: 10.1007/bf03348155] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
We have investigated the importance of the dopaminergic control of gonadotropin secretion by studying LH, FSH and PRL responses to L-dopa and bromocriptine in patients with polycystic ovary syndrome (PCOS). Both L-dopa and bromocriptine administration were followed by a statistically significant decrease in LH in the hyperprolactinemic PCO patients (compared to the normoprolactinemic subgroup - p less than 0.01 and control group - p less than 0.05); the decline was proportional to the basal level of LH. A significant positive correlation between basal LH levels and maximum net decrease of LH was observed after administration of both agents (p less than 0.01). Although both subgroups of PCO patients showed a similar decrease in PRL levels it was statistically significant only in the normoprolactinemic patients (p less than 0.01). Prolactin sensitivity to the inhibitory effect of bromocriptine and L-dopa showed a significant correlation with the basal PRL level (p less than 0.01). The response of serum FSH was variable and not significant. These results suggest that a reduction of an inhibitory influence of hypothalamic dopamine might be a cause of inappropriately elevated LH and PRL levels found in patients with polycystic ovary syndrome and hyperprolactinemia.
Collapse
Affiliation(s)
- G M Prelević
- Department of Endocrinology, Medical Centre "Zvezdara", Belgrade University School of Medicine, Beograd, Yugoslavia
| | | | | |
Collapse
|
9
|
Abstract
In order to investigate the postulated relationship between hyperprolactinaemia and polycystic ovary syndrome (PCOS) we have studied 62 patients with PCOS. Only two patients had persistent prolactin (PRL) concentrations greater than the normal range on both random sampling and after blood sampling from intravenous cannula over 2 hours. Twenty-eight of the remaining patients had basal PRL secretion studied in more detail. Samples were collected at 15 min intervals during a 6 h period in all 28 patients and hourly samples were collected overnight from four patients. Results failed to demonstrate differences from control subjects in mean basal PRL concentrations, in spontaneous fluctuations or in increments related to stress, food or sleep. Lactotroph response to thyrotrophin releasing hormone, luteinising hormone releasing hormone and insulin stress testing in PCOS were determined. Results confirm a previous observation that normal PRL increments occur after ovulation and a blunted response follows a period of anovulation. This study has failed to find a consistent abnormality of lactotroph function in patients with PCOS other than that associated with anovulation.
Collapse
|
10
|
Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Fossati P. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 1985; 44:356-60. [PMID: 3161758 DOI: 10.1016/s0015-0282(16)48860-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Thirty-two women presenting with polycystic ovary syndrome (PCO) were studied on 3 consecutive days. On day 1, plasma androstenedione, testosterone, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), 17-hydroxyprogesterone (17-OHP), estrone (E1), estradiol, serum prolactin (PRL), and PRL response to thyrotropin-releasing hormone were determined. On day 2 the patients were given two placebos at 1-hour intervals; then serum PRL, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) and the LH and FSH responses to LH-releasing hormone (LH-RH) were determined. On day 3 the patients were given two 2.5-mg tablets of bromocriptine (BRCR) at 12-hour intervals; then serum PRL, LH, and FSH and the LH and FSH responses to LH-RH were again determined. After BRCR, mean values of basal serum PRL (P less than 0.001), LH (P less than 0.05), and FSH (P less than 0.001) and the FSH response to LH-RH (P less than 0.01) fell with respect to the values determined on day 2. Our group of patients was heterogeneous regarding the effects of BRCR upon the LH response to LH-RH. Of 32 women undergoing the trial, 17 did not respond to BRCR (change of the LH response to LH-RH less than 33% with respect to day 2). They were called "nonresponders." Among the 15 who responded to BRCR, 10 decreased their LH response greater than or equal to 33% ("decreasers") and 5 increased their LH response greater than or equal to 33% ("increasers"). Decreasers had mean values of serum PRL, plasma E1, DHEA-S, and 17-OHP higher than nonresponders (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
11
|
Rönnberg L, Ylöstalo P, Ruokonen A. Hormonal parameters and conception rate during five different types of treatment of polycystic ovarian syndrome. Int J Gynaecol Obstet 1985; 23:177-83. [PMID: 2865178 DOI: 10.1016/0020-7292(85)90101-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Hormonal parameters and conception rate of 66 women with polycystic ovarian syndrome (PCO) were studied in a prospective way. Main therapy was clomiphene citrate (N 25) for 6 cycles. Previous clomiphene failures (N 23) underwent ovarian wedge resection, and they who did not menstruate after wedge resection (N 9) received further clomiphene as above. Patients, who did not want to conceive, were treated with dydrogesterone (N 11) or with an estrogen-progestin combination pill (N 7). Clomiphene citrate and ovarian wedge resection decreased luteal phase FSH and LH levels, increased serum estradiol and resulted in frequent ovulations (clomiphene 80%, wedge resection 45%, wedge resection + clomiphene 67%) and pregnancies (clomiphene 60%, wedge resection 36%, wedge resection + 67%), whereas cyclic progestin and estrogen-progestin treatment lowered elevated serum testosterone concentrations without influencing on FSH or luteinizing hormone (LH) levels. Thus clomiphene citrate seems to be the therapy of choice in infertile PCO patients, whereas progestin or estrogen-progestin lower the elevated testosterone concentrations in serum.
Collapse
|
12
|
Castracane VD, Wright E, Czar PL. The effect of testosterone on human chorionic gonadotropin-stimulated ovarian steroidogenesis in vivo in the baboon (Papio cynocephalus). Fertil Steril 1983; 40:683-7. [PMID: 6628714 DOI: 10.1016/s0015-0282(16)47431-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
We have studied the effect of exogenously induced hyperandrogenism on the ovarian response to human chorionic gonadotropin (hCG) in the baboon. Normally cycling baboons were treated with increasing daily doses of hCG for 5 consecutive days from day 10 of the luteal phase (n = 5). Hyperandrogenic baboons received the same hCG regimen 1 hour after a Silastic capsule containing crystalline testosterone (T) had been implanted under the skin (n = 3). Control animals received an empty Silastic capsule (n = 8). All baboons were bled on alternate days from days 6 to 20 of the luteal phase, and daily during hCG treatment. T capsules induced immediate hyperandrogenism, with T levels several times greater than normal luteal phase levels. The use of hCG resulted in an increase in plasma progesterone within 24 hours and levels gradually declined thereafter. Estradiol increased rapidly and remained elevated during hCG treatment. In the presence of elevated T levels, hCG had a significantly reduced effect on the magnitude and duration of plasma progesterone increase. The effect of hCG on plasma estradiol levels was virtually eliminated in hyperandrogenic baboons. This study seems to demonstrate a direct inhibitory effect of T on ovarian steroidogenesis in vivo and may explain the ovarian changes that occur in hyperandrogenic women.
Collapse
|
13
|
Buvat J, Ardaens K, Lemaire A, Gauthier A, Gasnault JP, Buvat-Herbaut M. Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil Steril 1983; 39:700-3. [PMID: 6404663 DOI: 10.1016/s0015-0282(16)47069-x] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Twenty-five subfertile men, all presenting with idiopathic normogonadotropic oligospermia, were treated with tamoxifen (20 mg/day) for 4 to 12 months. Semen analysis was performed twice before treatment and at least twice after 3 to 12 months of treatment. In 14 patients, serum luteinizing hormone (LH), serum follicle-stimulating hormone (FSH), and plasma testosterone (T) were assayed before treatment, then again after 2 weeks and 12 weeks of treatment. Semen volume, sperm motility, and sperm morphologic characteristics were not modified by tamoxifen. Conversely, a twofold increase of both the mean sperm concentration and the mean total sperm count per ejaculate was observed during treatment (P less than 0.001). Mean values of T, LH, and FSH increased during treatment, but the difference was only significant for T (P less than 0.001) and FSH (P less than 0.05). Ten pregnancies (40% of cases) were reported during the 161 months of treatment.
Collapse
|